Cartesian Therapeutics (RNAC) EBIT Margin (2015 - 2026)
Cartesian Therapeutics (RNAC) reported EBIT Margin of 33973.08% for Q1 2026, down 3198317.0% year-over-year from N/an in Q1 2025, and down 726.42% quarter-over-quarter from 5423.38% in Q4 2025.
Cartesian Therapeutics (RNAC) EBIT Margin (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of EBIT Margin data on file, last reported at 33973.08% in Q1 2026.
- EBIT Margin for Q1 2026 came in at 33973.08%, down 3198317.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 16088.59% (up 1624577.0% YoY), and the FY2025 annual result was 35851.25%, down 3573656.0% from the prior year.
- EBIT Margin declined to 33973.08% in Q1 2026 per RNAC's latest filing, from 5423.38% in the prior quarter.
- Over five years, EBIT Margin peaked at 5423.38% in Q4 2025 and troughed at 33973.08% in Q1 2026.
- A 5-year average of 2456.89% and a median of 214.0% in 2024 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2025 and 2026: EBIT Margin jumped 350992 bps in 2025, then sank 3198317 bps in 2026.
- A 5-year view of EBIT Margin shows it stood at 50.59% in 2022, then sank by 769 bps to 439.54% in 2023, then jumped by 535 bps to 1913.46% in 2024, then soared by 183 bps to 5423.38% in 2025, then plunged by 726 bps to 33973.08% in 2026.
- Business Quant data shows RNAC's EBIT Margin at 33973.08% in Q1 2026, 5423.38% in Q4 2025, and 4660.62% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - | -33,973.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33,973.08% |
| Dec 31, 2025 | 5,423.38% |
| Sep 30, 2025 | -4,660.62% |
| Mar 31, 2025 | -1,989.91% |
| Dec 31, 2024 | 1,913.46% |
| Sep 30, 2024 | -4,541.34% |
| Jun 30, 2024 | 41.35% |
| Mar 31, 2024 | -228.56% |
| Dec 31, 2023 | -439.54% |
| Sep 30, 2023 | -199.44% |
| Jun 30, 2023 | -355.08% |
| Mar 31, 2023 | -309.55% |
| Dec 31, 2022 | -50.59% |
| Sep 30, 2022 | -7.72% |
| Jun 30, 2022 | 35.29% |
| Mar 31, 2022 | 31.69% |
| Dec 31, 2021 | 13.62% |
| Sep 30, 2021 | -8.06% |
| Jun 30, 2021 | 2.30% |
| Mar 31, 2021 | -64.78% |